Cargando…
The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan
Introduction Dapagliflozin is a member of a novel class of drugs (sodium-glucose cotransporter-2 inhibitors) used to treat type 2 diabetes mellitus and licensed in Pakistan in 2017. This retrospective observational study evaluated the effects of dapagliflozin on glycated hemoglobin (HbA1c) concentra...
Autores principales: | Kamin, Matiullah, Ishtiaq, Osama, Raashid, Kashif, Wahab, Muhammad Umar, Khan, Sajjad Ali, Raja, Umar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294883/ https://www.ncbi.nlm.nih.gov/pubmed/32550088 http://dx.doi.org/10.7759/cureus.8565 |
Ejemplares similares
-
Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan
por: Kamin, Matiullah, et al.
Publicado: (2021) -
Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
por: Zameer, Rafia, et al.
Publicado: (2020) -
Weight and Body Mass Index for Predicting Thyroxine Dose in Primary Hypothyroidism
por: Raashid, Kashif, et al.
Publicado: (2021) -
Endocrinological Manifestations of Sanjad-Sakati Syndrome
por: Bashar, Masharib, et al.
Publicado: (2020) -
Exploring the Indications, Levels, and Outcomes of Lower Extremity Amputation at a Tertiary Care Hospital in Pakistan
por: Khatoon, Malik Amna, et al.
Publicado: (2023)